-
The updated International Health Regulations: good news for global health equity Lancet (IF 98.4) Pub Date : 2024-06-17 Ashley Bloomfield, Abdullah Assiri
-
A programme for greater health equity for the next UK Government Lancet (IF 98.4) Pub Date : 2024-06-13 Michael Marmot, Jessica Allen
-
Optimising treatment for chronic subdural haematoma Lancet (IF 98.4) Pub Date : 2024-06-06 Keita Shibahashi
-
Burr-hole drainage with or without irrigation for chronic subdural haematoma (FINISH): a Finnish, nationwide, parallel-group, multicentre, randomised, controlled, non-inferiority trial Lancet (IF 98.4) Pub Date : 2024-06-06 Rahul Raj MD PhD, Pihla Tommiska MD PhD, Timo Koivisto MD PhD, Prof Ville Leinonen MD PhD, Nils Danner MD PhD, Jussi P Posti MD PhD, Dan Laukka MD PhD, Teemu Luoto MD PhD, Minna Rauhala MD PhD, Sami Tetri MD PhD, Tommi K Korhonen MD PhD, Jarno Satopää MD PhD, Riku Kivisaari MD PhD, Teemu Luostarinen MD PhD, Christoph Schwartz MD MHBA, Tomasz Czuba MSc, Simo Taimela MD PhD, Kimmo Lönnrot MD PhD, Prof
Chronic subdural haematoma is a common surgically treated intracranial emergency. Burr-hole drainage surgery, to evacuate chronic subdural haematoma, involves three elements: creation of a burr hole for access, irrigation of the subdural space, and insertion of a subdural drain. Although the subdural drain has been established as beneficial, the therapeutic effect of subdural irrigation has not been
-
The developing role of theranostics in NETs Lancet (IF 98.4) Pub Date : 2024-06-05 Robert A Ramirez, Cathy Eng
-
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study Lancet (IF 98.4) Pub Date : 2024-06-05 Simron Singh MD, Daniel Halperin MD, Sten Myrehaug MD, Ken Herrmann MD, Prof Marianne Pavel MD, Pamela L Kunz MD, Beth Chasen MD, Salvatore Tafuto MD, Secondo Lastoria MD, Jaume Capdevila MD, Amparo García-Burillo MD, Do-Youn Oh MD, Changhoon Yoo MD, Thorvardur R Halfdanarson MD, Stephen Falk MD, Ilya Folitar MD, Yufen Zhang PhD, Paola Aimone MD, Wouter W de Herder MD, Diego Ferone MD, all the NETTER-2
There are currently no standard first-line treatment options for patients with higher grade 2–3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [Lu]Lu-DOTA-TATE (Lu-Dotatate) treatment. NETTER-2 was an open-label, randomised, parallel-group, superiority, phase 3 trial. We enrolled patients (aged ≥15 years)
-
Aftercare for surgically treated ankle fractures Lancet (IF 98.4) Pub Date : 2024-06-04 Tim Schepers, Jens A Halm
-
Early versus delayed weight-bearing following operatively treated ankle fracture (WAX): a non-inferiority, multicentre, randomised controlled trial Lancet (IF 98.4) Pub Date : 2024-06-04 Christopher Patrick Bretherton PhD, Juul Achten PhD, Vidoushee Jogarah MSc, Prof Stavros Petrou PhD, Nicholas Peckham MSc, Felix Achana PhD, Duncan Appelbe PhD, Prof Rebecca Kearney PhD, Harry Claireux MBChB, Philip Bell PhD, Prof Xavier L Griffin PhD, WAX Investigators, Andrew McAndrew, Neal Jacobs, Justin Forder, Thomas Hester, Charlotte Cross, Tony Bateman, Will Kieffer, Tristan Barton, Richard
After surgery for a broken ankle, patients are usually instructed to avoid walking for 6 weeks (delayed weight-bearing). Walking 2 weeks after surgery (early weight-bearing) might be a safe and preferable rehabilitation strategy. This study aimed to determine the clinical and cost effectiveness of an early weight-bearing strategy compared with a delayed weight-bearing strategy. This was a pragmatic
-
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet (IF 98.4) Pub Date : 2024-06-03 Prof Hans Gelderblom MD, Vivek Bhadri MD, Silvia Stacchiotti MD, Prof Sebastian Bauer MD, Andrew J Wagner MD, Prof Michiel van de Sande MD, Nicholas M Bernthal MD, Antonio López Pousa MD, Albiruni Abdul Razak BM BCh, Prof Antoine Italiano MD, Mahbubl Ahmed MD, Prof Axel Le Cesne MD, Gabriel Tinoco MD, Kjetil Boye MD, Javier Martín-Broto MD, Emanuela Palmerini MD, Salvatore Tafuto MD, Sarah Pratap DPhil
Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control, CSF1R inhibitor, in patients with symptomatic TGCT not amenable to surgery. MOTION is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 35 specialised hospitals in
-
Vimseltinib for tenosynovial giant cell tumour Lancet (IF 98.4) Pub Date : 2024-06-03 Hiroshi Urakawa, Shiro Imagama
-
Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success Lancet (IF 98.4) Pub Date : 2024-05-30 Nabil F Saba
-
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial Lancet (IF 98.4) Pub Date : 2024-05-30 Xu Liu MD, Yuan Zhang MD, Prof Kun-Yu Yang MD, Prof Ning Zhang MD, Prof Feng Jin MD, Prof Guo-Rong Zou MD, Prof Xiao-Dong Zhu MD, Prof Fang-Yun Xie MD, Xiao-Yu Liang MD, Wen-Fei Li MD, Prof Zhen-Yu He MD, Prof Nian-Yong Chen MD, Prof Wei-Han Hu MD, Hai-Jun Wu MD, Prof Mei Shi MD, Guan-Qun Zhou MD, Prof Yan-Ping Mao MD, Rui Guo MD, Rui Sun MD, Jing Huang MD, Shao-Qiang Liang MD, Wei-Li Wu MD, Zhen Su
Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains unknown in patients with locoregionally advanced nasopharyngeal carcinoma. We assessed the addition of sintilimab, a PD-1 inhibitor, to standard chemoradiotherapy in this patient population. This multicentre, open-label, parallel-group
-
Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study Lancet (IF 98.4) Pub Date : 2024-05-29 Kenneth Chan MRCP, Elizabeth Wahome PhD, Apostolos Tsiachristas PhD, Alexios S Antonopoulos PhD, Parijat Patel BSc, Maria Lyasheva MPhil, Lucy Kingham BSc, Henry West DPhil, Evangelos K Oikonomou DPhil, Lucrezia Volpe BSc, Michail C Mavrogiannis MD, Edward Nicol FRCP, Tarun K Mittal FRCR, Thomas Halborg MSc, Rafail A Kotronias MRCP, David Adlam DPhil, Bhavik Modi PhD, Jonathan Rodrigues PhD, Nicholas
Coronary computed tomography angiography (CCTA) is the first line investigation for chest pain, and it is used to guide revascularisation. However, the widespread adoption of CCTA has revealed a large group of individuals without obstructive coronary artery disease (CAD), with unclear prognosis and management. Measurement of coronary inflammation from CCTA using the perivascular fat attenuation index
-
Blowing in the wind—India's health data and transparency issues Lancet (IF 98.4) Pub Date : 2024-05-29 Prajna Anirvan
-
A balanced perspective on India's health data and transparency Lancet (IF 98.4) Pub Date : 2024-05-29 Gururaj Arakeri, U S Vishal Rao
-
Responding to India's data and transparency Lancet (IF 98.4) Pub Date : 2024-05-29 Prasanta Raghab Mohapatra
-
Suerie Moon: bridging the nexus of research, practice, and policy Lancet (IF 98.4) Pub Date : 2024-05-24 Pamela Das
-
A health strategy for chlordecone (Kepone) exposure in the French Territories of America Lancet (IF 98.4) Pub Date : 2024-05-24 Dabor Resiere, Fréderic Lapostolle, Jonathan Florentin, Rishika Banydeen, Papa Gueye, Jean Pujo, Bruno Mégarbane, Hatem Kallel, Rémi Névière
-
Organ donation in refractory cardiac arrest Lancet (IF 98.4) Pub Date : 2024-05-24 Tal Soumagnac, Jean-Herlé Raphalen, Richard Chocron, Alice Hutin, Lionel Lamhaut
-
Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach Lancet (IF 98.4) Pub Date : 2024-05-23 Prof Marc Mendelson PhD, Joseph A Lewnard PhD, Prof Mike Sharland MD, Aislinn Cook MSc, Koen B Pouwels PhD, Yewande Alimi MPH, Mirfin Mpundu DRPH, Evelyn Wesangula MSc, Prof Jeffrey Scott Weese PhD, Prof John-Arne Røttingen PhD, Prof Ramanan Laxminarayan PhD
Rising antimicrobial resistance (AMR) is a global health crisis for countries of all economic levels, alongside the broader challenge of access to antibiotics. As a result, development goals for child survival, healthy ageing, poverty reduction, and food security are at risk. Preserving antimicrobial effectiveness, a global public good, requires political will, targets, accountability frameworks, and
-
Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance Lancet (IF 98.4) Pub Date : 2024-05-23 Prof Ramanan Laxminarayan PhD, Isabella Impalli BSE, Radha Rangarajan PhD, Jennifer Cohn MD, Kavi Ramjeet PhD, Betsy Wonderly Trainor BSc, Prof Steffanie Strathdee PhD, Nithima Sumpradit PhD, Daniel Berman MIA, Prof Heiman Wertheim PhD, Prof Kevin Outterson JD, Padmini Srikantiah MD, Ursula Theuretzbacher PhD
The increasing number of bacterial infections globally that do not respond to any available antibiotics indicates a need to invest in—and ensure access to—new antibiotics, vaccines, and diagnostics. The traditional model of drug development, which depends on substantial revenues to motivate investment, is no longer economically viable without push and pull incentives. Moreover, drugs developed through
-
Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa Lancet (IF 98.4) Pub Date : 2024-05-23 Elisa Molinelli, Oriana Simonetti
-
-
Ramanan Laxminarayan: seeking sustainable access to antibiotics Lancet (IF 98.4) Pub Date : 2024-05-23 Udani Samarasekera
-
Antimicrobial resistance survivors: calling the world to action Lancet (IF 98.4) Pub Date : 2024-05-23 Nour Shamas, John Kariuki, Ella Balasa, Tori Kinamon, Felix Liauw, Sue Charles, Brandon Jaka, Rob Purdie, Bhakti Chavan, Mashood Oluku Lawal, Anthony Darcovich, Vanessa Carter
-
The scope of the antimicrobial resistance challenge Lancet (IF 98.4) Pub Date : 2024-05-23 Prof Iruka N Okeke PhD, Marlieke E A de Kraker PhD, Thomas P Van Boeckel PhD, Chirag K Kumar BA, Prof Heike Schmitt PhD, Prof Ana C Gales MD PhD, Silvia Bertagnolio MD, Prof Mike Sharland MD, Prof Ramanan Laxminarayan PhD
Each year, an estimated 7·7 million deaths are attributed to bacterial infections, of which 4.95 million are associated with drug-resistant pathogens, and 1·27 million are caused by bacterial pathogens resistant to the antibiotics available. Access to effective antibiotics when indicated prolongs life, reduces disability, reduces health-care expenses, and enables access to other life-saving medical
-
Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis Lancet (IF 98.4) Pub Date : 2024-05-23 Joseph A Lewnard PhD, Esmita Charani PhD, Alec Gleason BSc, Prof Li Yang Hsu MBBS, Wasif Ali Khan MHS, Abhilasha Karkey DPhil, Prof Clare I R Chandler PhD, Tapfumanei Mashe PhD, Prof Ejaz Ahmed Khan MD, Andre N H Bulabula PhD, Pilar Donado-Godoy PhD, Prof Ramanan Laxminarayan PhD
National action plans enumerate many interventions as potential strategies to reduce the burden of bacterial antimicrobial resistance (AMR). However, knowledge of the benefits achievable by specific approaches is needed to inform policy making, especially in low-income and middle-income countries (LMICs) with substantial AMR burden and low health-care system capacity. In a modelling analysis, we estimated
-
-
-
-
Infected blood report release marks a day of shame for the UK Lancet (IF 98.4) Pub Date : 2024-05-23 Jacqui Thornton
-
-
Caesarean section: the history of a controversial operation Lancet (IF 98.4) Pub Date : 2024-05-23 Sally Frampton
-
-
Expanded Programme on Immunization at 50 years: its legacy and future Lancet (IF 98.4) Pub Date : 2024-05-23 Brian Wahl, Virginia E Pitzer
-
A right atrial mass and colonic cancer in a patient with Lynch syndrome Lancet (IF 98.4) Pub Date : 2024-05-23 Stéphane Ederhy MD, Pierre Demondion MD, Amal Ali MD, Prof Françoise Montravers MD PhD, Baptiste Cervantes MD, Prof Pierre Fouret MD PhD, Prof Ariel Cohen MD PhD, Prof Thierry Andre MD PhD
-
The Beni-Koji scandal and Japan's unique health food system Lancet (IF 98.4) Pub Date : 2024-05-23 Takanao Hashimoto, Akihiko Ozaki, Hayase Hakariya, Kenzo Takahashi, Tetsuya Tanimoto
-
Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa – Authors' reply Lancet (IF 98.4) Pub Date : 2024-05-23 Shabbar Jaffar
-
Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa Lancet (IF 98.4) Pub Date : 2024-05-23 Diane Havlir, Moses R Kamya, Maya Petersen
-
Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa Lancet (IF 98.4) Pub Date : 2024-05-23 Songtao Cai, Zhijie Xu, Yang Zhao, Liesl Zühlke
-
Gene therapy proves successful in treating hereditary deafness Lancet (IF 98.4) Pub Date : 2024-05-23 Ellen Reisinger, Ivana Trapani
-
Antimicrobial resistance and people living with disabilities Lancet (IF 98.4) Pub Date : 2024-05-23 Yusuff Adebayo Adebisi
-
Why not eliminate HTLV-1 while eliminating HIV-1? Lancet (IF 98.4) Pub Date : 2024-05-23 Goedele N Maertens, Damian F J Purcell, Carolina Rosadas, Daniel Bradshaw, Mirna Biglione, Graham P Taylor, Fabiola Martin
-
Purpura fulminans in young women with influenza and co-infections Lancet (IF 98.4) Pub Date : 2024-05-23 Matthew Brown, John Gerrard, Catherine McDougall, Julie MacPhail, Olivia Williams
-
Expedited approvals and adverse drug reactions in women Lancet (IF 98.4) Pub Date : 2024-05-23 Constance Viehbeck
-
Global workforce implications of Dobbs v Jackson Women's Health Organization Lancet (IF 98.4) Pub Date : 2024-05-22 Julia Strasser, Ramatou Ouedraogo, Sarah Baird, Ernestina Coast
-
New-generation Myval transcatheter heart valve in severe aortic stenosis Lancet (IF 98.4) Pub Date : 2024-05-22 Mariama Akodad, Emmanuel Gall
-
LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial Lancet (IF 98.4) Pub Date : 2024-05-22 Prof Andreas Baumbach MD, Prof Niels van Royen PhD, Ignacio J Amat-Santos PhD, Martin Hudec PhD, Matjaz Bunc PhD, Alexander Ijsselmuiden PhD, Peep Laanmets MD, Daniel Unic PhD, Prof Bela Merkely MD, Renicus S Hermanides PhD, Vlasis Ninios MD, Prof Marcin Protasiewicz PhD, Benno J W M Rensing PhD, Pedro L Martin PhD, Fausto Feres MD, Manuel De Sousa Almeida PhD, Prof Eric van Belle PhD, Prof Axel Linke
Transcatheter aortic valve implantation is an established, guideline-endorsed treatment for severe aortic stenosis. Precise sizing of the balloon-expandable Myval transcatheter heart valve (THV) series with the aortic annulus is facilitated by increasing its diameter in 1·5 mm increments, compared with the usual 3 mm increments in valve size. The LANDMARK trial aimed to show non-inferiority of the
-
Health-care workforce implications of the Dobbs v Jackson Women's Health Organization decision Lancet (IF 98.4) Pub Date : 2024-05-22 Prof Claire D Brindis DrPH, Melissa H Laitner PhD, Prof Ellen Wright Clayton JD MD, Prof Susan C Scrimshaw PhD, Prof Barbara J Grosz PhD, Prof Lisa A Simpson MB, Prof Sara Rosenbaum JD, Corale L Brierley PhD, Prof Melissa A Simon MD, Yvette Roubideaux MD, Prof Bruce N Calonge MD, Prof Paula A Johnson MD, Laura DeStefano BA, Ashley Bear PhD, Kavita S Arora MD, Prof Victor J Dzau MD
The Supreme Court decision, which revoked the constitutional right to abortion in the USA, has impacted the national medical workforce. Impacts vary across states, but providers in states with restrictive abortion laws now must contend with evolving legal and ethical challenges that have the potential to affect workforce safety, mental health, education, and training opportunities, in addition to having
-
Societal implications of the Dobbs v Jackson Women's Health Organization decision Lancet (IF 98.4) Pub Date : 2024-05-22 Prof Claire D Brindis DrPH, Melissa H Laitner PhD, Prof Ellen Wright Clayton JD MD, Prof Susan C Scrimshaw PhD, Prof Barbara J Grosz PhD, Prof Lisa A Simpson MB, Prof Sara Rosenbaum JD, Corale L Brierley PhD, Prof Melissa A Simon MD, Yvette Roubideaux MD, Prof Bruce N Calonge MD, Prof Paula A Johnson MD, Laura DeStefano BA, Ashley Bear PhD, Kavita S Arora MD, Prof Victor J Dzau MD
On June 24, 2022, the US Supreme Court's decision in marked the removal of the constitutional right to abortion in the USA, introducing a complex ethical and legal landscape for patients and providers. This shift has had immediate health and equity repercussions, but it is also crucial to examine the broader impacts on states, health-care systems, and society as a whole. Restrictions on abortion access
-
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials Lancet (IF 98.4) Pub Date : 2024-05-22 Prof Alexa B Kimball MD, Prof Gregor B E Jemec DMSci, Christopher J Sayed MD, Prof Joslyn S Kirby MD, Prof Errol Prens PhD, John R Ingram DM, Prof Amit Garg PhD, Prof Alice B Gottlieb MD, Prof Jacek C Szepietowski PhD, Prof Falk G Bechara MD, Prof Evangelos J Giamarellos-Bourboulis MD, Hideki Fujita PhD, Robert Rolleri PharmD, Paulatsya Joshi MD, Pratiksha Dokhe MD, Edward Muller MSc, Luke Peterson
Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, in patients with moderate-to-severe hidradenitis suppurativa. BE HEARD I and II were two identically designed, 48-week randomised, double-blind, placebo-controlled
-
Bariatric surgery in women with PCOS and obesity Lancet (IF 98.4) Pub Date : 2024-05-20 Laure Morin-Papunen
-
Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial Lancet (IF 98.4) Pub Date : 2024-05-20 Suhaniya N S Samarasinghe PhD, Bianca Leca MD, Shahd Alabdulkader PhD, Georgios K Dimitriadis PhD, Allan Davasgaium MSc, Puja Thadani MSc, Kate Parry RD, Migena Luli BSc, Karen O'Donnell BSc, Brett Johnson MSc, Ali Abbara PhD, Florian Seyfried PhD, Rachel Morman, Ahmed R Ahmed PhD, Sherif Hakky PhD, Christos Tsironis MSc, Prof Sanjay Purkayastha MD, Prof Carel W le Roux PhD, Prof Stephen Franks MD
Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. Obesity exacerbates the reproductive complications of PCOS; however, the management of obesity in women with PCOS remains a large unmet clinical need. Observational studies have indicated that bariatric surgery could improve the rates of ovulatory cycles and prospects of fertility; however, the efficacy of surgery
-
Strengthening health systems through surgery Lancet (IF 98.4) Pub Date : 2024-05-20 Dmitri Nepogodiev, Lawani Ismail, John G Meara, April C Roslani, Ewen M Harrison, Aneel Bhangu
-
Advances and challenges in the acute treatment of minor ischaemic stroke Lancet (IF 98.4) Pub Date : 2024-05-17 Simona Sacco, Guillaume Turc
-
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial Lancet (IF 98.4) Pub Date : 2024-05-17 Prof Shelagh B Coutts MD, Sandeep Ankolekar FRCP, Ramana Appireddy MD, Juan F Arenillas PhD, Zarina Assis MD, Peter Bailey MD, Philip A Barber MD, Prof Rodrigo Bazan MD, Brian H Buck MD, Prof Ken S Butcher PhD, Prof Marie-Christine Camden MD, Prof Bruce C V Campbell PhD, Leanne K Casaubon MD, Luciana Catanese MD, Prof Kausik Chatterjee MD, Philip M C Choi MBChB, Brian Clarke MRCPI, Prof Dar Dowlatshahi
Individuals with minor ischaemic stroke and intracranial occlusion are at increased risk of poor outcomes. Intravenous thrombolysis with tenecteplase might improve outcomes in this population. We aimed to test the superiority of intravenous tenecteplase over non-thrombolytic standard of care in patients with minor ischaemic stroke and intracranial occlusion or focal perfusion abnormality. In this multicentre
-
-
-
Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management Lancet (IF 98.4) Pub Date : 2024-05-16 Alan Pollack, Alan Dal Pra
-
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial Lancet (IF 98.4) Pub Date : 2024-05-16 Prof Chris C Parker MD, Prof Howard Kynaston MD, Adrian D Cook MSc, Prof Noel W Clarke ChM, Prof Charles N Catton FRCPC, William R Cross PhD, Peter M Petersen PhD, Prof Rajendra A Persad FRCS(Urol), Cheryl A Pugh BSc, Prof Fred Saad MD, John Logue FRCR, Prof Heather Payne FRCR, Lorna C Bower PGCert, Chris Brawley MSc, Mary Rauchenberger PhD, Maroie Barkati MD, David M Bottomley FRCR, Klaus Brasso PhD
Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report